Open-label Study of Bevacizumab Maintenance Therapy (AVASTINĀ®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival
tumour assessment before cycle 3, at 2nd cycle of maintenance therapy and every 9 weeks thereafter
No
Clinical Trials
Study Director
Hoffmann-La Roche
Russia: Ministry of Health of the Russian Federation
MO22089
NCT00961415
July 2009
October 2012
Name | Location |
---|